Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants who did not need escape therapy (as… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants who did not need escape therapy (as… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review